1
项与 Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床试验A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
100 项与 Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果
100 项与 Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学
100 项与 Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利(医药)
100 项与 Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易